Home
Drugs
Bortezomib
Clinical Trials

Clinical Trials Related to Bortezomib

Related studies linked through entity extraction aliases.

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Status: RECRUITING
Phase: PHASE2

Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

Status: TERMINATED
Phase: PHASE1

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Status: TERMINATED
Phase: PHASE2

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Status: WITHDRAWN
Phase: EARLY_PHASE1

DARA RVD For High Risk SMM

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics

Status: UNKNOWN
Phase: N/A

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Status: RECRUITING
Phase: PHASE2

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Status: TERMINATED
Phase: PHASE1

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Status: RECRUITING
Phase: PHASE3

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

Status: UNKNOWN
Phase: PHASE2

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Status: COMPLETED
Phase: PHASE2

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Status: RECRUITING
Phase: PHASE2

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Status: WITHDRAWN
Phase: PHASE1

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Status: TERMINATED
Phase: PHASE2